menu
White Paper
December 19, 2018

A Next Generation Sequencing Approach to Influenza Vaccine Development

NGS approach to strain identification and genomic characterization of influenza
Influenza typing/identification is enabled by serological tests as well as genotyping of discrete regions of the viral genome. In contrast to Sanger sequencing, Next Generation Sequencing (NGS) provides a streamlined, high-throughput approach to strain identification and broader genomic characterization of influenza, including viral evolution in the wild or in response to vaccine or antiviral challenges.

We can use that sequence information to inform future development of vaccines and therapeutics. NGS presents new possibilities for influenza vaccine development. In this white paper, you will explore the challenges of developing influenza vaccines and new approaches that may eventually lead to a more universal solution.

Related Services:
Keeping Up with the Flu: Advances in seasonal influenza vaccine development

Vaccine and Infectious Disease Testing Capabilities

End-to-end Laboratory for Infectious Disease Testing and Vaccine Development

Harnessing innovative technologies for clinical trials involving emerging and re-emerging infectious diseases

Tools for better management of infectious disease clinical trials

A Next Generation Sequencing (NGS) Approach to Influenza Vaccine Development

NGS influenza typing assay for vaccine and therapeutic development

Read More